This company not only should escape Europe’s troubles, it should benefit from them.
This trend is driving the markets right now.
I hate goodbyes. So, rather than get all sappy and sentimental, I'm just gonna say, "Thank you."
The Supreme Court said Tuesday that investors who lost millions when Merck pulled its blockbuster pain drug Vioxx off the market can go ahead with a lawsuit against the pharmaceutical giant.
Amgen says better sales of its anti-infection drugs helped lift first-quarter profit 15 percent, but cautions that health care reform measures will tamp down full-year results.
My last day at CNBC is May 7th. I've decided to make a career change. Because my next act will include working within the health care sector, to avoid even the appearance of a conflict in my remaining days here at CNBC, I won't be blogging or reporting anymore about stock-related stories on my previous beat.
Portugal and Spain provide as good as an example as The Netherlands. In both countries, the drug is illegal, but you'd never know it based on some quirky technicalities. The general trend is about prevention, not punishment.
Here, we present the top 10 class-action lawsuits in the United States either won, settled or pending, and in terms of damages sought as compiled by LawInfo.com.
Because of a drug factory shutdown, Jeannine Lipez of Lock Haven, Pa., says she can no longer even walk across the street without getting spasms in her left leg and will probably need an operation to replace an artery.
With a nod to my colleague Jane Wells' "Funny Business" blog and at the risk of getting armies of pharma sales reps mad at me, I am sending out a DVR alert for Episode 15 from the second season of an HBO animated comedy called, "The Life And Times Of Tim."
A few months ago I blogged that Pops had taken the bold step of jumping on Twitter and actually tweeting (that's Twitter-speak for sending out messages of 140 characters or less.) Well, now, a sell-side biotech analyst is tweeting, too.
Butler's Gordon Hayward threw a closing buzzer, half-court, long shot against Duke last night. It was oh-so-close. But when Butler coach Brad Stevens threw caution to the wind 10 years ago, it turns out it was a slam dunk.
Ray Elliott put in less than six months on the job last year at Boston Scientific as the medical device maker's new CEO. But, according to "The New York Times," in that short amount of time Elliott received enough total compensation to make him the second-highest paid head honcho behind only Oracle's Larry Ellison (albeit a distant #2.)
Former chairman of the Federal Reserve Alan Greenspan reinforced increasingly confident assessments by the Obama administration that the nation’s latest job numbers reveal a resurgent economy.
FDA advisory committee votes sometimes end in confusion. First, because the actual vote often gets all convoluted and recounted as some panelists hem and haw about voting thumbs up or thumbs down and try to equivocate their decision. And second, because no matter how many times I've explained it to people here, the votes get misread and miscommunicated as actual approval or rejection of a drug versus a recommendation that the FDA clear or spike a drug.
The world’s largest drug company, Pfizer, has handled mergers badly, invented too few drugs and left its reputation in disrepair after two criminal cases. And that is the assessment of its own chief executive. The NYT talks to Pfizer CEO Jeffrey Kindler.
But, oh! The irony. At a meeting designed to convince the Street the company is well on its way to correcting a major manufacturing problem, a simple technical glitch keeps executives from conveying that message to a broader, off-site audience.
A federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property. The NYT reports.
Electronic health records are a good first step, but represent only one aspect of how IT can improve America’s healthcare system by making it seamless and safer, writes Chris Begley, Chairman & CEO, Hospira, Inc.
You need to buy the paper edition for $5 or subscribe to the website to see it for yourself, but Barron's has put only one biopharma honcho on its annual list of the world's top-30 CEOs.